Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance.

The vaccinia virus complement control protein (VCP) is involved in modulating the host inflammatory response by blocking both pathways of complement activity through its ability to bind C3b and C4b. Other activities arise from VCP's ability to strongly bind heparin. To map regions within VCP involved in binding complement and heparin experimentally, surface plasmon resonance (SPR) and recombinantly expressed VCP (rVCP) constructs were employed. Using C3b or heparin as the immobilized ligand, various rVCP constructs were tested for their ability to bind. Results suggest that VCP is the smallest functional unit able to bind C3b, thereby blocking complement activity, and only a single site, the large basic region near the C-terminus, is involved in heparin binding. Kinetic analysis was also performed to determine the relative binding affinities between rVCP and complement (C3-MA and C4b), as well as rVCP and heparin. rVCP was found to possess a significantly greater affinity for C3-MA than C4b, as indicated by the 1.50e3-fold greater association rate constant (k(a)). This study provides insights for the design of new therapeutic proteins capable of blocking complement activation.

[1]  John D Lambris,et al.  Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. , 2002, Virology.

[2]  B. Moss,et al.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Bromek,et al.  Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein. , 2001, Journal of molecular biology.

[4]  John D Lambris,et al.  Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. , 1998, Journal of immunology.

[5]  B. Nilsson,et al.  Complement C3b interactions studied with surface plasmon resonance technique. , 2001, International immunopharmacology.

[6]  W. Baldwin,et al.  Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). , 1999, Molecular immunology.

[7]  J. Atkinson,et al.  Structure-Function Analysis of the Active Sites of Complement Receptor Type 1* , 1998, The Journal of Biological Chemistry.

[8]  B. Moss,et al.  Regulation of complement activity by vaccinia virus complement-control protein. , 1992, The Journal of infectious diseases.

[9]  I. Campbell,et al.  NMR studies of a viral protein that mimics the regulators of complement activation. , 1997, Journal of molecular biology.

[10]  P. Zipfel,et al.  Identification of the second heparin-binding domain in human complement factor H. , 1998, Journal of immunology.

[11]  S. Shchelkunov,et al.  Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense , 2000, Journal of Virology.

[12]  G. Kotwal,et al.  VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN IS CAPABLE OF PROTECTING XENOENDOTHELIAL CELLS FROM ANTIBODY BINDING AND KILLING BY HUMAN COMPLEMENT AND CYTOTOXIC CELLS1 , 2001, Transplantation.

[13]  G. Kotwal.  Poxviral mimicry of complement and chemokine system components: what's the end game? , 2000, Immunology today.

[14]  C. Mold,et al.  Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). , 1994, The Journal of biological chemistry.

[15]  S. Shchelkunov,et al.  The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. , 1997, Virology.

[16]  N. Thielens,et al.  Purification of human complement subcomponent C4 , 1979, FEBS letters.

[17]  K. Murthy,et al.  RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate Proteoglycans , 2001, Cell.

[18]  D. Hourcade,et al.  Decay Accelerating Activity of Complement Receptor Type 1 (CD35) , 1999, The Journal of Biological Chemistry.

[19]  H. Jarrett,et al.  Heparin elution of transcription factors from DNA-Sepharose columns. , 1999, Journal of chromatography. A.

[20]  H. Gresham,et al.  Isolation of human complement component C3 from small volumes of plasma. , 1986, Analytical biochemistry.

[21]  B. Moss,et al.  Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins , 1988, Nature.

[22]  B. Moss,et al.  Inhibition of the complement cascade by the major secretory protein of vaccinia virus. , 1990, Science.

[23]  S. Meri,et al.  Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. , 1994, Biochemical and biophysical research communications.

[24]  S. Meri,et al.  Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement1 2 , 2000, The Journal of Immunology.

[25]  A. Blom,et al.  A Cluster of Positively Charged Amino Acids in the C4BP α-Chain Is Crucial for C4b Binding and Factor I Cofactor Function* , 1999, The Journal of Biological Chemistry.

[26]  M. Thomas,et al.  Evidence for presence of an internal thiolester bond in third component of human complement. , 1980, Proceedings of the National Academy of Sciences of the United States of America.